Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19

Clinical pharmacokinetics; concepts and applications

1989 • 2,266 citations

The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.

1994 • 958 citations

Long-term omeprazole therapy in peptic ulcer disease: Gastrin, endocrine cell growth, and gastritis

1993 • 335 citations

Genetic polymorphism of S-mephenytoin hydroxylation

1989 • 292 citations

Omeprazole

1991 • 279 citations

Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism

1993 • 225 citations

Diazepam metabolism by human liver microsomes is mediated by both S‐ mephenytoin hydroxylase and CYP3A isoforms.

1994 • 223 citations

Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers

1995 • 216 citations

Interphenotype differences in disposition and effect on gastrin levels of omeprazole—suitability of omeprazole as a probe for CYP2C19.

1995 • 187 citations

Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects

1992 • 179 citations

Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism.

1994 • 144 citations

Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation.

1993 • 143 citations

Determination of omeprazole and metabolites in plasma and urine by liquid chromatography

1984 • 142 citations

Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population.

1992 • 140 citations

Increase of cytochrome P450IA2 activity by omeprazole: Evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin

1992 • 138 citations

Use of omeprazole in Zollinger‐Ellison syndrome: a prospective nine‐year study of efficacy and safety

1993 • 95 citations

Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects.

1990 • 89 citations

Specific and dose-dependent enzyme induction by omeprazole in human beings

1994 • 86 citations

Oral pharmacokinetics of omeprazole

1984 • 83 citations

Oxidative metabolism of lansoprazole by human liver cytochromes P450.

1995 • 77 citations

The Pharmacokinetics of Omeprazole in Humans—A Study of Single Intravenous and Oral Doses

1990 • 71 citations

New Oral Macrolide and Fluoroquinolone Antibiotics: An Overview of Pharmacokinetics, Interactions, and Safety

1993 • 68 citations

Phenotyping of CYP2C19 with enantiospecific HPLCquantification of R- and S-mephenytoin and comparison with the intron4/exon5 G??? A-splice site mutation

1995 • 56 citations

Zollinger-Ellison syndrome. Advances in treatment of gastric hypersecretion and the gastrinoma

1994 • 54 citations

Omeprazole and the induction of human cytochrome P-450: A response to concerns about potential adverse effects

1991 • 46 citations

Pharmacokinetics of oral and intravenous omeprazole in patients with the Zollinger-Ellison syndrome

1991 • 36 citations

Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment.

1995 • 35 citations

Safety of acid-suppressing drugs

1995 • 31 citations

Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer.

1991 • 23 citations

Inhibition of transketolase and pyruvate decarboxylase by omeprazole

1992 • 18 citations

The proton channel blocking agent omeprazole is an inhibitor of the thiamin shuttle

1990 • 17 citations

The influence of gastrointestinal agents on resorption and metabolism of cyclosporine after heart transplantation: experimental and clinical results.

1993 • 12 citations